Global Liquid Biopsy Market Opportunity & Technology Outlook 2020
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Biopsy is conducted to diagnose a disease, or to assess its progression so as to take an effective clinical action either by removing the affected site surgically or by drawing samples from the target tissue to conduct investigative studies about the disease. This technique is widespread and has been used since 12th century. The techniques involving solid biopsy have without any doubt, improved with advancement in scanning processes and surgical advancement. However, the traditional biopsy methods are of no match when it comes to the effective diagnosis and prognosis of cancer, besides ailments like renal failure, infections, fertility and transplantation related issues.
Liquid biopsy, on the other hand has offered us new insights in the diagnosis of diseases. It is the blood sample tests in which biomarkers associated with different disease are evaluated to determine the progression of a disease. This has allowed the emergence of targeted personalized diagnosis with increased efficiency outcomes and decreased diagnostic errors.
The emergence of liquid biopsy plays a vital role in prognosis as well as diagnostic studies for cancer treatment. Cancer has been one of the most difficult to be diagnosed at an early stage due to its fast mutation capabilities, immunosurveillance evading properties, circumventing growth suppressors among others. Besides, the genomic structure of cancer is highly unstable and in response to the therapy administered, cancer undergoes changes in their antigenic properties induced by mutations to escape immune action. Repeated tissue biopsy to assess the regression of the disease becomes cumbersome and dangerous for the patient. Therefore, the need arises for targeted therapy emerges, allowing real time monitoring to ensure that the targeted therapy is received by the cancer cells or to adopt a different biomarker in case the cancer cells mutate.
Liquid biopsy unlike normal biopsy is a non-invasive process in which samples can be drawn from blood, serum, saliva, urine or cerebral spinal fluid. Tissue biopsy on the other hand is invasive, costly, and painful and could be even risky in number of cases. Therefore, it becomes quite exciting to investigate the opportunities presented by liquid biopsies. For cancer diagnostic studies under liquid biopsy three techniques are normally used namely circulating tumor cells (CTCs), cell-free tumor nucleic acids (ctNA) and exosomes which includes small molecules like signal proteins, microRNAs, mRNAs, lipids, and exoDNA. Diagnosis of liquid biopsy is supplemented by the advancement in next generation sequencing techniques in which tumor cells, after they are captured, have their genomic and proteomic sequences run and analyzed using computational technologies to offer insight into the biomarkers associated with the respective tumor cells, which could then be in turn used for personalized diagnostic care.
“Global Liquid Biopsy Market Opportunity & Technology Outlook 2020” Report Highlights:
Biopsy is conducted to diagnose a disease, or to assess its progression so as to take an effective clinical action either by removing the affected site surgically or by drawing samples from the target tissue to conduct investigative studies about the disease. This technique is widespread and has been used since 12th century. The techniques involving solid biopsy have without any doubt, improved with advancement in scanning processes and surgical advancement. However, the traditional biopsy methods are of no match when it comes to the effective diagnosis and prognosis of cancer, besides ailments like renal failure, infections, fertility and transplantation related issues.
Liquid biopsy, on the other hand has offered us new insights in the diagnosis of diseases. It is the blood sample tests in which biomarkers associated with different disease are evaluated to determine the progression of a disease. This has allowed the emergence of targeted personalized diagnosis with increased efficiency outcomes and decreased diagnostic errors.
The emergence of liquid biopsy plays a vital role in prognosis as well as diagnostic studies for cancer treatment. Cancer has been one of the most difficult to be diagnosed at an early stage due to its fast mutation capabilities, immunosurveillance evading properties, circumventing growth suppressors among others. Besides, the genomic structure of cancer is highly unstable and in response to the therapy administered, cancer undergoes changes in their antigenic properties induced by mutations to escape immune action. Repeated tissue biopsy to assess the regression of the disease becomes cumbersome and dangerous for the patient. Therefore, the need arises for targeted therapy emerges, allowing real time monitoring to ensure that the targeted therapy is received by the cancer cells or to adopt a different biomarker in case the cancer cells mutate.
Liquid biopsy unlike normal biopsy is a non-invasive process in which samples can be drawn from blood, serum, saliva, urine or cerebral spinal fluid. Tissue biopsy on the other hand is invasive, costly, and painful and could be even risky in number of cases. Therefore, it becomes quite exciting to investigate the opportunities presented by liquid biopsies. For cancer diagnostic studies under liquid biopsy three techniques are normally used namely circulating tumor cells (CTCs), cell-free tumor nucleic acids (ctNA) and exosomes which includes small molecules like signal proteins, microRNAs, mRNAs, lipids, and exoDNA. Diagnosis of liquid biopsy is supplemented by the advancement in next generation sequencing techniques in which tumor cells, after they are captured, have their genomic and proteomic sequences run and analyzed using computational technologies to offer insight into the biomarkers associated with the respective tumor cells, which could then be in turn used for personalized diagnostic care.
“Global Liquid Biopsy Market Opportunity & Technology Outlook 2020” Report Highlights:
- Introduction & Mechanism of Action of Liquid Biopsy
- Diagnostic Technological Advancement Supplementing Liquid Biopsy Market
- Clinical Investigation Using Cell-Free Circulating Tumor DNA for Different Indications
- Combinational Analysis on the Working of Circulating Tumor Cells & Cell-Free Tumor DNA
- Market Share of Different Liquid Biopsy Techniques
- Business Model of Liquid Biopsy Market
1. INTRODUCTION TO LIQUID BIOPSY: A NON-INVASIVE, GAME-CHANGER DIAGNOSTIC TOOL
2. MECHANISM OF ACTION: MAJOR COMPONENTS OF LIQUID BIOPSY
2.1 Circulating Tumor Cells
2.1.1 Parameters Guiding Circulating Cell Tumors
2.2 Circulating Tumor Nucleic Acids (ctNA)
2.2.1 Cell-Free Tumor DNA
2.2.2 Other Circulatory Tumor Nucleic Acid: microRNA, mRNA & Long Non-Coding RNAs
2.3 Exosomes
3. CIRCULATORY TUMOR CELLS: A SNAPSHOT; ITS HISTORY, BIOLOGICS, SELECTION METHOD, DETECTION PROCEDURES, ENRICHMENT PROCEDURES, ANALYSIS & DISEASE MONITORING
3.1 The History & Introduction
3.2 The Selection Methods
3.3 The Analysis Methodologies
3.4 The Scope of Disease Monitoring
3.5 The Biologics of Circulatory Tumor Cells
4. DIAGNOSTIC TECHNOLOGICAL ADVANCEMENT SUPPLEMENTING LIQUID BIOPSY MARKET
4.1 Glimpses to the Next Generation Sequencing Techniques
4.2 Methodologies Involved in the Next Generation Sequencing
4.2.1 Genomics
4.2.2 Transcriptomics
4.2.3 Epigenomics
4.3 Flowchart Depicting Genomic Analysis Using Next Generation Sequencing
4.3.1 A Basic Workflow of Next Generation Sequencers
4.3.2 Integrated Data Analysis
4.4 Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market
5. CLINICAL INVESTIGATION USING CELL-FREE CIRCULATING TUMOR DNA FOR DIFFERENT INDICATIONS
5.1 Lung Cancer
5.2 Breast Cancer
5.3 Colorectal Cancer
5.4 Melanoma
5.5 Gastric Cancer
5.6 Prostate Cancer
5.7 Brain Cancer
5.8 Detection & Monitoring of Type 1 Diabetes
5.9 Pancreatic Cancer
5.10 Renal Cancer
5.11 Retinoblastoma
6. COMBINATIONAL ANALYSIS ON THE WORKING OF CIRCULATING TUMOR CELLS & CELL-FREE TUMOR DNA
7. BUSINESS MODEL OF LIQUID BIOPSY MARKET: A HOTBED FOR START-UPS AND VENTURE CAPITAL FUNDING
8. OTHER MARKET MODALITIES ASSOCIATED WITH LIQUID BIOPSY
8.1 Accreditation through Clinical Laboratory Improvement Amendments (CLIA) Testing: Green Signal for Liquid Biopsy
8.2 The Impact of Service Providers in Liquid Biopsy Market
8.3 The Role of Liquid Biopsy In The Light Of Insurance Associated Issues
9. LIQUID BIOPSY MARKET SHARE IN NORTH AMERICA, EUROPE, ASIA- PACIFIC & REST OF THE WORLD
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World
9.4.1 Africa
9.4.2 South America
9.4.3 Middle East
10. MARKET DRIVERS: CLINICAL UTILITIES OF LIQUID BIOPSY. WHY DO WE NEED THEM?
10.1 Help Monitor Minimal Residue Disease
10.2 Help Track Emergence of Drug Resistance
10.3 Liquid Biopsy Used As a Predictive & Pharmacodynamic Biomarker
10.3.1 Cell-Free Tumor DNA as Predictive Biomarker
10.3.2 Cell-Free Tumor DNA as Pharmacodynamic Biomarker
11. MARKET TRENDS IN LIQUID BIOPSY. IS THE ERA OF TISSUE BIOPSY COMING TO AN END?
12. MARKET SHARE OF DIFFERENT LIQUID BIOPSY TECHNIQUES
13. MARKET CHALLENGES: LIQUID BIOPSY, A REVOLUTION IN CANCER DIAGNOSIS; A MYTH OR A REALITY?
13.1 Complex Immuno-Biochemical Mechanism of Cancer Cells
13.2 The Risk of False Positive Liquid Biopsy Test
13.3 The Risk of False Negative Liquid Biopsy Test
13.4 Inconclusive Nature of Cancer Biomarkers
13.5 Lack of Standardized Protocols
13.6 Business Model Based Challenges
13.7 Issues Related To Regulatory Framework
14. CONCLUSION: LIQUID BIOPSY; REAL-TIME & REVOLUTIONARY NOVEL DIAGNOSTIC TOOL
15. COMPETITIVE LANDSCAPE
15.1 AdnaGen (QIAGEN)
15.2 Agena Bioscience
15.3 Angle
15.4 ApoCell
15.5 Biocept
15.6 BioFluidica
15.7 Bio-Rad Laboratories
15.8 Boreal Genomics
15.9 Chronix Biomedical
15.10 Clearbridge BioMedics
15.11 Cynvenio
15.12 Cytotrack
15.13 Epic Sciences
15.14 Exosome Diagnostics
15.15 Fluidigm
15.16 Fluxion Biosciences
15.17 Genomic Health
15.18 Guardant Health
15.19 HansaBiomed
15.20 Horizon Discovery
15.21 iCellate
15.22 Illumina
15.23 Inivata
15.24 Janssen Diagnostics
15.25 Molecular MD
15.26 Myriad Genetics
15.27 Natera
2. MECHANISM OF ACTION: MAJOR COMPONENTS OF LIQUID BIOPSY
2.1 Circulating Tumor Cells
2.1.1 Parameters Guiding Circulating Cell Tumors
2.2 Circulating Tumor Nucleic Acids (ctNA)
2.2.1 Cell-Free Tumor DNA
2.2.2 Other Circulatory Tumor Nucleic Acid: microRNA, mRNA & Long Non-Coding RNAs
2.3 Exosomes
3. CIRCULATORY TUMOR CELLS: A SNAPSHOT; ITS HISTORY, BIOLOGICS, SELECTION METHOD, DETECTION PROCEDURES, ENRICHMENT PROCEDURES, ANALYSIS & DISEASE MONITORING
3.1 The History & Introduction
3.2 The Selection Methods
3.3 The Analysis Methodologies
3.4 The Scope of Disease Monitoring
3.5 The Biologics of Circulatory Tumor Cells
4. DIAGNOSTIC TECHNOLOGICAL ADVANCEMENT SUPPLEMENTING LIQUID BIOPSY MARKET
4.1 Glimpses to the Next Generation Sequencing Techniques
4.2 Methodologies Involved in the Next Generation Sequencing
4.2.1 Genomics
4.2.2 Transcriptomics
4.2.3 Epigenomics
4.3 Flowchart Depicting Genomic Analysis Using Next Generation Sequencing
4.3.1 A Basic Workflow of Next Generation Sequencers
4.3.2 Integrated Data Analysis
4.4 Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market
5. CLINICAL INVESTIGATION USING CELL-FREE CIRCULATING TUMOR DNA FOR DIFFERENT INDICATIONS
5.1 Lung Cancer
5.2 Breast Cancer
5.3 Colorectal Cancer
5.4 Melanoma
5.5 Gastric Cancer
5.6 Prostate Cancer
5.7 Brain Cancer
5.8 Detection & Monitoring of Type 1 Diabetes
5.9 Pancreatic Cancer
5.10 Renal Cancer
5.11 Retinoblastoma
6. COMBINATIONAL ANALYSIS ON THE WORKING OF CIRCULATING TUMOR CELLS & CELL-FREE TUMOR DNA
7. BUSINESS MODEL OF LIQUID BIOPSY MARKET: A HOTBED FOR START-UPS AND VENTURE CAPITAL FUNDING
8. OTHER MARKET MODALITIES ASSOCIATED WITH LIQUID BIOPSY
8.1 Accreditation through Clinical Laboratory Improvement Amendments (CLIA) Testing: Green Signal for Liquid Biopsy
8.2 The Impact of Service Providers in Liquid Biopsy Market
8.3 The Role of Liquid Biopsy In The Light Of Insurance Associated Issues
9. LIQUID BIOPSY MARKET SHARE IN NORTH AMERICA, EUROPE, ASIA- PACIFIC & REST OF THE WORLD
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World
9.4.1 Africa
9.4.2 South America
9.4.3 Middle East
10. MARKET DRIVERS: CLINICAL UTILITIES OF LIQUID BIOPSY. WHY DO WE NEED THEM?
10.1 Help Monitor Minimal Residue Disease
10.2 Help Track Emergence of Drug Resistance
10.3 Liquid Biopsy Used As a Predictive & Pharmacodynamic Biomarker
10.3.1 Cell-Free Tumor DNA as Predictive Biomarker
10.3.2 Cell-Free Tumor DNA as Pharmacodynamic Biomarker
11. MARKET TRENDS IN LIQUID BIOPSY. IS THE ERA OF TISSUE BIOPSY COMING TO AN END?
12. MARKET SHARE OF DIFFERENT LIQUID BIOPSY TECHNIQUES
13. MARKET CHALLENGES: LIQUID BIOPSY, A REVOLUTION IN CANCER DIAGNOSIS; A MYTH OR A REALITY?
13.1 Complex Immuno-Biochemical Mechanism of Cancer Cells
13.2 The Risk of False Positive Liquid Biopsy Test
13.3 The Risk of False Negative Liquid Biopsy Test
13.4 Inconclusive Nature of Cancer Biomarkers
13.5 Lack of Standardized Protocols
13.6 Business Model Based Challenges
13.7 Issues Related To Regulatory Framework
14. CONCLUSION: LIQUID BIOPSY; REAL-TIME & REVOLUTIONARY NOVEL DIAGNOSTIC TOOL
15. COMPETITIVE LANDSCAPE
15.1 AdnaGen (QIAGEN)
15.2 Agena Bioscience
15.3 Angle
15.4 ApoCell
15.5 Biocept
15.6 BioFluidica
15.7 Bio-Rad Laboratories
15.8 Boreal Genomics
15.9 Chronix Biomedical
15.10 Clearbridge BioMedics
15.11 Cynvenio
15.12 Cytotrack
15.13 Epic Sciences
15.14 Exosome Diagnostics
15.15 Fluidigm
15.16 Fluxion Biosciences
15.17 Genomic Health
15.18 Guardant Health
15.19 HansaBiomed
15.20 Horizon Discovery
15.21 iCellate
15.22 Illumina
15.23 Inivata
15.24 Janssen Diagnostics
15.25 Molecular MD
15.26 Myriad Genetics
15.27 Natera
LIST OF FIGURES
Figure 1-1: Limitations of Tissue Biopsy
Figure 1-2: Hallmarks of Cancer Cells
Figure 1-3: Advantages of Liquid Biopsy
Figure 2-1: Major Components of Liquid Biopsy
Figure 2-2: Properties of Circulatory Tumor Cells
Figure 2-3: Techniques Guiding Circulating Cell Tumors Separation
Figure 2-4: Cell-Free Tumor DNA
Figure 2-5: Other Circulatory Tumor Nucleic Acid
Figure 2-6: Exosomes Based Liquid Biopsy
Figure 3-1: Introduction to Circulatory Tumor Cells
Figure 3-2: Selection Methods of Circulating Tumor Cells
Figure 3-3: The Analysis Methodologies for Circulatory Tumor Cells
Figure 3-4: The Scope of Disease Monitoring With Circulatory Tumor Cell
Figure 3-5: The Biologics of Circulatory Tumor Cells
Figure 4-1: Methodologies Involved In the Next Generation Sequencing
Figure 4-2: Genomics Attributes of Next Generation Sequencing
Figure 4-3: Proteomic Attributes of Next Generation Sequencing
Figure 4-4: Epigenomic Attributes of Next Generation Sequencing
Figure 4-5: Flowchart Depicting Genomic Analysis Using Next Generation Sequencing
Figure 4-6: Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market
Figure 5-1: Liquid Biopsy for Detection of Lung Cancer
Figure 5-2: Liquid Biopsy for Detection of Breast Cancer
Figure 5-3: Liquid Biopsy for Detection of Colorectal Cancer
Figure 5-4: Liquid Biopsy for Detection of Melanoma
Figure 5-5: Liquid Biopsy for Detection of Gastric Cancer
Figure 5-6: Liquid Biopsy for Detection of Prostate Cancer
Figure 5-7: Liquid Biopsy for Detection of Brain Cancer
Figure 5-8: Detection & Monitoring of Type 1 Diabetes
Figure 5-9: Liquid Biopsy for Detection of Pancreatic Cancer
Figure 5-10: Liquid Biopsy for Detection of Renal Cancer
Figure 5-11: Liquid Biopsy for Detection of Retinoblastoma
Figure 6-1: Circulating Tumor Cells & Cell-free Tumor DNA
Figure 6-2: Differential Study of Circulating Tumor Cells & Cell-free Tumor DNA
Figure 7-1: Liquid Biopsy for Start-Ups & Venture Capitalists; Favorable Factors
Figure 8-1: Accreditation Program for Liquid Biopsy
Figure 8-2: Service Providers in Liquid Biopsy Market
Figure 8-3: Liquid Biopsy & Insurance Coverage Plans
Figure 9-1: Liquid Biopsy Market in North America
Figure 9-2: Liquid Biopsy Market in Europe
Figure 9-3: Liquid Biopsy Market in Asia-Pacific Region
Figure 9-4: Liquid Biopsy Market in Rest of the World
Figure 10-1: Liquid Biopsy in Monitoring Minimal Residual Disease
Figure 10-2: Liquid Biopsy in Tracking Emergence of Drug Resistance
Figure 10-3: Liquid Biopsy as a Predictive & Pharmacodynamic Biomarker
Figure 11-1: Market Trends in Liquid Biopsy
Figure 12-1: Liquid Biopsy Market by Technique
Figure 13-1: Market Challenges Associated With Liquid Biopsy
Figure 1-1: Limitations of Tissue Biopsy
Figure 1-2: Hallmarks of Cancer Cells
Figure 1-3: Advantages of Liquid Biopsy
Figure 2-1: Major Components of Liquid Biopsy
Figure 2-2: Properties of Circulatory Tumor Cells
Figure 2-3: Techniques Guiding Circulating Cell Tumors Separation
Figure 2-4: Cell-Free Tumor DNA
Figure 2-5: Other Circulatory Tumor Nucleic Acid
Figure 2-6: Exosomes Based Liquid Biopsy
Figure 3-1: Introduction to Circulatory Tumor Cells
Figure 3-2: Selection Methods of Circulating Tumor Cells
Figure 3-3: The Analysis Methodologies for Circulatory Tumor Cells
Figure 3-4: The Scope of Disease Monitoring With Circulatory Tumor Cell
Figure 3-5: The Biologics of Circulatory Tumor Cells
Figure 4-1: Methodologies Involved In the Next Generation Sequencing
Figure 4-2: Genomics Attributes of Next Generation Sequencing
Figure 4-3: Proteomic Attributes of Next Generation Sequencing
Figure 4-4: Epigenomic Attributes of Next Generation Sequencing
Figure 4-5: Flowchart Depicting Genomic Analysis Using Next Generation Sequencing
Figure 4-6: Pricing Implications of Next Generation Sequencing On the Liquid Biopsy Market
Figure 5-1: Liquid Biopsy for Detection of Lung Cancer
Figure 5-2: Liquid Biopsy for Detection of Breast Cancer
Figure 5-3: Liquid Biopsy for Detection of Colorectal Cancer
Figure 5-4: Liquid Biopsy for Detection of Melanoma
Figure 5-5: Liquid Biopsy for Detection of Gastric Cancer
Figure 5-6: Liquid Biopsy for Detection of Prostate Cancer
Figure 5-7: Liquid Biopsy for Detection of Brain Cancer
Figure 5-8: Detection & Monitoring of Type 1 Diabetes
Figure 5-9: Liquid Biopsy for Detection of Pancreatic Cancer
Figure 5-10: Liquid Biopsy for Detection of Renal Cancer
Figure 5-11: Liquid Biopsy for Detection of Retinoblastoma
Figure 6-1: Circulating Tumor Cells & Cell-free Tumor DNA
Figure 6-2: Differential Study of Circulating Tumor Cells & Cell-free Tumor DNA
Figure 7-1: Liquid Biopsy for Start-Ups & Venture Capitalists; Favorable Factors
Figure 8-1: Accreditation Program for Liquid Biopsy
Figure 8-2: Service Providers in Liquid Biopsy Market
Figure 8-3: Liquid Biopsy & Insurance Coverage Plans
Figure 9-1: Liquid Biopsy Market in North America
Figure 9-2: Liquid Biopsy Market in Europe
Figure 9-3: Liquid Biopsy Market in Asia-Pacific Region
Figure 9-4: Liquid Biopsy Market in Rest of the World
Figure 10-1: Liquid Biopsy in Monitoring Minimal Residual Disease
Figure 10-2: Liquid Biopsy in Tracking Emergence of Drug Resistance
Figure 10-3: Liquid Biopsy as a Predictive & Pharmacodynamic Biomarker
Figure 11-1: Market Trends in Liquid Biopsy
Figure 12-1: Liquid Biopsy Market by Technique
Figure 13-1: Market Challenges Associated With Liquid Biopsy
